<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Labour: induction; Prostaglandins: obstetrics; Uterine: stimulants; Carbetocin; Abortion: induction; Pregnancy: termination; Gemeprost; Misoprostol: obstetrics; Dinoprostone; Mifepristone; Syntocinon; Abortion: haemorrhage; Haemorrhage: abortion; Haemorrhage: postpartum; Uterine: bleeding; Ergometrine; Oxytocin; Syntometrine" /><meta name="IX" content="Labour: induction; Prostaglandins: obstetrics; Uterine: stimulants; Carbetocin; Abortion: induction; Pregnancy: termination; Gemeprost; Misoprostol: obstetrics; Dinoprostone; Mifepristone; Syntocinon; Abortion: haemorrhage; Haemorrhage: abortion; Haemorrhage: postpartum; Uterine: bleeding; Ergometrine; Oxytocin; Syntometrine" /><title>7.1.1 Prostaglandins and oxytocics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP4760-prostaglandins-and-oxytocics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP4760-prostaglandins-and-oxytocics.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP4760-prostaglandins-and-oxytocics.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP4758-obstetrics-gynaecology-and-urinary-tract-disorders.htm">7 Obstetrics, gynaecology, and urinary-tract disorders</a> &gt; <a href="PHP4759-drugs-used-in-obstetrics.htm">7.1 Drugs used in obstetrics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP4759-drugs-used-in-obstetrics.htm" title="Previous: 7.1 Drugs used in obstetrics">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP4765-carbetocin.htm" title="Next: CARBETOCIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>7.1.1 </span>Prostaglandins and oxytocics</h1><?highlighter on?><div id="pC" class="jN"><p>Prostaglandins and oxytocics are used to induce abortion or induce or augment labour and to minimise blood loss from the placental site. They include oxytocin, carbetocin, ergometrine, and the prostaglandins. All induce uterine contractions with varying degrees of pain according to the strength of contractions induced.</p> <div id="PHP4761"><h2>Induction of abortion</h2><p><strong>Gemeprost</strong>, a prostaglandin administered vaginally as pessaries, is suitable for the medical induction of late therapeutic abortion; gemeprost is also used to ripen the cervix before surgical abortion, particularly in primigravidas. The prostaglandin <strong>misoprostol</strong> (<a title="sub-section: Mifepristone" href="PHP4786-mifepristone.htm">section 7.1.2</a>) is given by mouth or by vaginal administration to induce medical abortion [unlicensed indication]; intravaginal use ripens the cervix before surgical abortion [unlicensed indication]. Extra-amniotic <strong>dinoprostone</strong> is rarely used nowadays.</p><p>Pre-treatment with <strong>mifepristone</strong> (<a title="sub-section: Mifepristone" href="PHP4786-mifepristone.htm">section 7.1.2</a>) can facilitate the process of medical abortion. It sensitises the uterus to subsequent administration of a prostaglandin and, therefore, abortion occurs in a shorter time and with a lower dose of prostaglandin.</p></div>  <div id="PHP4762"><h2>Induction and augmentation of labour</h2><p><strong>Dinoprostone</strong> is available as vaginal tablets, pessaries and vaginal gels for the induction of labour. The intravenous solution is rarely used; it is associated with more side-effects.</p><p><strong>Oxytocin</strong> (<em>Syntocinon</em>®) is administered by slow intravenous infusion, using an infusion pump, to induce or augment labour, usually in conjunction with amniotomy. Uterine activity must be monitored carefully and hyperstimulation avoided. Large doses of oxytocin may result in excessive fluid retention. </p><p><strong>Misoprostol</strong> is given orally or vaginally for the induction of labour [unlicensed indication].</p></div> <div id="PHP4763" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Induction of labour (updated July 2008)</h3><p>Available at <a href="http://www.nice.org.uk">www.nice.org.uk</a></p></div> <div id="PHP4764"><h2>Prevention and treatment of haemorrhage</h2><p>Bleeding due to incomplete miscarriage or abortion can be controlled with <strong>ergometrine</strong> and <strong>oxytocin</strong> (<em>Syntometrine®</em>) given intramuscularly, the dose is adjusted according to the patient's condition and blood loss. This is commonly used before surgical evacuation of the uterus, particularly when surgery is delayed. Oxytocin and ergometrine combined are more effective in early pregnancy than either drug alone.</p><p>Active management of the third stage of labour reduces the risk of postpartum haemorrhage; oxytocin is given by intramuscular injection [unlicensed] on delivery of the anterior shoulder or, at the latest, immediately after the baby is delivered. Alternatively, ergometrine 500 micrograms with oxytocin 5 units (<em>Syntometrine®</em> 1 mL) can be given by intramuscular injection in the absence of hypertension; oxytocin alone causes less nausea, vomiting, and hypertension than when given with ergometrine.</p><p>In excessive uterine bleeding, any placental products remaining in the uterus should be removed. Oxytocic drugs are used to treat postpartum haemorrhage caused by uterine atony; treatment options are as follows:</p><ul><li><p>oxytocin 5 units by slow intravenous injection (dose may be repeated), followed in severe cases by intravenous infusion of oxytocin 40 units in 500 mL infusion fluid (prolonged administration—see <a title="BNF:preparation: Oxytocin" href="PHP9443-oxytocin.htm">Appendix 4</a>) at a rate that controls uterine atony <em>or</em></p> </li><li><p>ergometrine 250–500 micrograms by intramuscular injection <em>or</em></p> </li><li><p>ergometrine 250–500 micrograms by slow intravenous injection (use with caution—risk of hypertension) <em>or</em></p> </li><li><p>ergometrine 500 micrograms with oxytocin 5 units (<em>Syntometrine</em>® 1 mL) by intramuscular injection</p> </li></ul><p><strong>Carboprost</strong> has an important role in severe postpartum haemorrhage unresponsive to ergometrine and oxytocin.</p><p><strong>Misoprostol</strong> [unlicensed] can be used in postpartum haemorrhage when oxytocin, ergometrine, and carboprost are not available or are inappropriate.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP4765-carbetocin"><a href="PHP4765-carbetocin.htm" title="CARBETOCIN">CARBETOCIN</a></li><li id="_PHP4767-carboprost"><a href="PHP4767-carboprost.htm" title="CARBOPROST">CARBOPROST</a></li><li id="_PHP4769-dinoprostone"><a href="PHP4769-dinoprostone.htm" title="DINOPROSTONE">DINOPROSTONE</a></li><li id="_PHP4772-ergometrine-maleate"><a href="PHP4772-ergometrine-maleate.htm" title="ERGOMETRINE MALEATE">ERGOMETRINE MALEATE</a></li><li id="_PHP4778-gemeprost"><a href="PHP4778-gemeprost.htm" title="GEMEPROST">GEMEPROST</a></li><li id="_PHP4780-oxytocin"><a href="PHP4780-oxytocin.htm" title="OXYTOCIN">OXYTOCIN</a></li><li><a href="PHP4783-drugs-affecting-the-ductus-arteriosus.htm" title="7.1.1.1 Drugs affecting the ductus arteriosus">7.1.1.1 Drugs affecting the ductus arteriosus</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP4759-drugs-used-in-obstetrics.htm">Previous: 7.1 Drugs used in obstetrics</a> | <a class="top" href="PHP4760-prostaglandins-and-oxytocics.htm#">Top</a> | <a accesskey="]" href="PHP4765-carbetocin.htm">Next: CARBETOCIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>